{"abortion spontaneous": 2.33, "abscess": 10.94, "adverse event": 2.38, "alanine aminotransferase increased": 4.41, "application site erythema": 3.32, "aspartate aminotransferase increased": 4.31, "ataxia": 3.85, "autoimmune hepatitis": 10.76, "autoimmune thyroiditis": 6.46, "cardiomyopathy": 4.42, "cellulitis": 4.37, "depressed mood": 2.49, "depression": 3.77, "device operational issue": 36.0, "drug delivery system malfunction": 10.9, "drug-induced liver injury": 2.16, "erysipelas": 5.77, "expanded disability status scale score increased": 183.97, "gait disturbance": 3.28, "gait inability": 2.35, "gamma-glutamyltransferase increased": 8.04, "hemiparesis": 2.89, "hemiplegia": 2.77, "hepatic enzyme increased": 3.31, "hepatic steatosis": 3.47, "hepatitis": 3.42, "hyperthyroidism": 2.76, "impaired healing": 2.61, "incorrect dose administered by device": 14.69, "influenza like illness": 4.66, "injection site abscess": 142.54, "injection site atrophy": 81.63, "injection site bruising": 8.85, "injection site cellulitis": 71.91, "injection site discolouration": 40.41, "injection site erythema": 5.4, "injection site haematoma": 3.03, "injection site haemorrhage": 7.82, "injection site induration": 14.68, "injection site infection": 64.42, "injection site inflammation": 2.67, "injection site mass": 12.34, "injection site necrosis": 236.22, "injection site nodule": 12.77, "injection site oedema": 4.44, "injection site pain": 2.98, "injection site rash": 7.18, "injection site reaction": 10.3, "injection site ulcer": 174.51, "jaundice": 2.66, "leukopenia": 3.33, "liver function test increased": 12.53, "lymphocyte count decreased": 6.11, "lymphopenia": 3.1, "maternal exposure during pregcy": 2.57, "mobility decreased": 3.14, "multiple sclerosis": 58.94, "multiple sclerosis relapse": 61.83, "muscle rigidity": 2.49, "muscle spasticity": 21.09, "muscular weakness": 2.92, "nephrotic syndrome": 4.32, "neuromyelitis optica spectrum disorder": 27.55, "optic neuritis": 14.45, "panniculitis": 19.9, "paralysis": 2.61, "paraparesis": 12.47, "product dose omission issue": 3.54, "proteinuria": 2.17, "psychotic disorder": 2.07, "raynaud's phenomenon": 5.64, "secondary progressive multiple sclerosis": 68.28, "sensory disturbance": 2.23, "skin necrosis": 31.21, "skin reaction": 5.08, "skin ulcer": 3.08, "thrombotic microangiopathy": 10.64, "transaminases increased": 3.98, "urinary incontinence": 2.01}